Sign in
Taking peoplePhase 2

A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

Key facts

Who runs it
GlaxoSmithKline
Where
Gabon and Uganda2 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
70 people, planned
Started
7 Oct 2026
Expected to end
8 Oct 2027
Type of study
Interventional, 5 groups
Treatments tested
  • GSK3772701 600 mg
  • GSK3772701 900 mg
  • GSK3772701 150 mg
  • GSK3772701 400 mg
  • GSK3772701 50 mg
Record updated
10 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Male and female patients aged 18 to 65 years
  • Presence of malaria due to mono-infection with P. falciparum confirmed by:; Fever, as defined by axillary temperature >=37.5°C or oral/tympanic temperature >=38°C and,; Microscopically confirmed P. falciparum malaria parasite mono-infection,; A parasite count between 2,000 to 60,000 asexual parasite count/µL of blood for P. falciparum
  • Have a BMI between >=18 and <=30 kg/m2
  • Able to swallow oral medication
  • Signed informed consent, acknowledging understanding and willingness to comply with the requirements of the study. If the patient is unable to write, thumb print consent, signed by an impartial witness is permitted according to local ethical considerations
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:; Is a woman of non-childbearing potential (WONCBP) or; Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method, from Study Day 1, and during the study intervention period (40 +/-3 days)

Who cannot take part

  • Significant illness within two weeks prior to screening
  • Known history or evidence (based on clinical examination or investigation) of uncontrolled active cardiovascular disease (including hypertension), respiratory disease (including active tuberculosis even if treatment is ongoing), liver cirrhosis or liver disease (based on prior investigation, clinical signs and/or interpretation of liver enzymes), other active hepatic, renal, gastrointestinal, immunological, neurological, endocrine, infectious, or psychiatric disease
  • Have received any antimalarial treatment in the preceding 6 weeks (see Section 6.10), as determined by history or medical record
  • Prior enrolment in this study and receipt of treatment with GSK3772701
  • Use of other investigational drugs at the time of enrolment, or within 6 weeks, or 5 half-lives prior to enrolment into this study, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations
  • History of drug or alcohol abuse within 3 months prior to dosing, or clinical evidence of such abuse
  • Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention; Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention; Note: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing
  • Mixed Plasmodium infection, i.e., infection with more than one malaria (plasmodium) species (by microscopy; participant to be withdrawn from study treatment if PCR subsequently indicates presence of mixed infection)
  • History of malignancy (or current malignancy) of any organ system (other than localized carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
  • Positive HIV antibody test at screening, or history of HIV infection based on past positive test result, clinical record or current treatment
  • Anaemia (Hb <=8.0g/dl) or known clinically important chronic underlying haematological disease such as sickle cell disease at screening
  • Significant chronic medical conditions which in the opinion of the investigator preclude enrolment into the study
  • History of hypersensitivity to the study drug or drug formulation and capsule (Hypromellose (hydroxypropyl methylcellulose)) constituents
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Any clinically significant ECG abnormalities at Screening unrelated to malaria (including but not limited to, second degree AV block (Mobitz Type 2), complete heart block, ST changes, atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, prolonged QT interval
  • Creatinine >=2 x ULN
  • ALT >2.0 x ULN
  • Total bilirubin >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is <=1.5xULN
  • Patients with signs and symptoms of severe/complicated malaria according to the WHO 2024 Criteria
  • Abnormal values: QTcF >450 msec or QTcF >480 msec for patients with bundle branch block
  • Severe vomiting, defined as more than 3 times in the 24 hours before screening or inability to tolerate oral treatment
  • Severe diarrhoea defined as more than 3 watery stools per day in the 24 hours before screening
  • Participants who in the opinion of the Investigator are unsuitable for participation in the study or cannot be enrolled due to logistical reasons

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

The 5 groups in the trial

  • Cohort 1_Single DoseTreatment being tested

    Participants receive a single GSK3772701 600 mg dose on Day 1.

    Treatment: GSK3772701 600 mg

  • Cohort 2_ Single DoseTreatment being tested

    Participants receive a single GSK3772701 900 mg dose on Day 1.

    Treatment: GSK3772701 900 mg

  • Cohort 3_ Repeat DoseTreatment being tested

    Participants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2.

    Treatment: GSK3772701 150 mg

  • Cohort 4_ Repeat DoseTreatment being tested

    Participants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2.

    Treatment: GSK3772701 400 mg

  • Cohort 5_ Repeat DoseTreatment being tested

    Participants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3.

    Treatment: GSK3772701 50 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria
Criteria questions
Built from NCT07545681, who can take part
Record updated
10 November 2026